Less Ads, More Data, More Tools Register for FREE

Pin to quick picksABC.L Regulatory News (ABC)

  • There is currently no data for ABC

Director/PDMR Shareholding

9 Nov 2009 18:04

RNS Number : 2318C
ABCAM Plc
09 November 2009
 



For immediate release

9 November 2009

ABCAM PLC

("Abcam" or "the Company")

Director/PDMR Dealings: LTIP

Cambridge, UK: Abcam plc (AIM: ABC), the rapidly growing bioscience company that markets antibodies via its own online catalogue, announces that on 9 November 2009 the Remuneration Committee granted the following conditional nil cost share awards at a price of 904 pence per ordinary share (the closing share price on 6 November 2009) to the Executive Directors of the Company under the Abcam plc Long-Term Incentive Plan (the "LTIP"):

Name

Number of Ordinary Shares subject to the

LTIP Award

Jonathan Milner

27,399

Jim Warwick

24,744

Jeff Iliffe

23,416

The shares subject to the LTIP awards issued to Executive Directors will be released in three years' time subject to continued employment and subject to the satisfaction of certain specific performance conditions based on:

the Company's Comparative Total Shareholder Return performance against a Comparator Group of companies; and 
growth in Earnings per Share.

In addition, the following PDMRs were also granted LTIP awards in accordance with the rules of the LTIP:

Name

Number of Ordinary Shares subject to the

LTIP Award

Mark Bushfield

8,151

Jane Cooke

2,895

Philippe Cotrel

8,151

The shares subject to the LTIP awards issued to PDMRs will vest in three years' time subject to the achievement of specific performance criteria.

For further information please contact:

Abcam

+ 44 (0) 1223 696000

Jonathan Milner, Chief Executive Officer

Jeffrey Iliffe, Chief Financial Officer

Numis Securities

+ 44 (0) 20 7260 1000

Michael Meade / Nick Westlake - Nominated Adviser

James Black - Corporate Broking

Buchanan Communications

+ 44 (0) 20 7466 5000

Mark Court / Stasa Filiplic

Notes for editors:

About Abcam plc

Abcam is a producer and distributor of research-grade antibodies headquartered in CambridgeUnited Kingdom, with offices in CambridgeMassachusettsUSATokyoJapan and Hong Kong. Abcam was admitted to AIM in November 2005 and trades under the ticker symbol ABC. The Company produces and distributes its own and third-party produced antibodies to academic and commercial users throughout the world. Product ordering is available through the Company's website www.abcam.com, where customers are also able to access up-to-date and detailed technical product data sheets. All the antibodies are sold under the Abcam brand name and the Company's vision is to build the world's largest online resource of high-quality and commercially viable antibodies. Abcam now has an online catalogue of over 56,000 products, most of which are antibodies, from over 250 suppliers and employs 243 staff in its four operating companies.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSVKLFBKFBBFBX
Date   Source Headline
1st Oct 20204:41 pmRNSTotal Voting Rights
25th Sep 20201:33 pmRNSDirector/PDMR Shareholding
18th Sep 20202:19 pmRNSBlock listing Interim Review
18th Sep 20207:54 amRNSDirector/PDMR Shareholding
14th Sep 20207:00 amRNSFull Year Results 2020
11th Sep 202010:34 amRNSNotice of Results
1st Sep 20207:52 amRNSTotal Voting Rights
4th Aug 202012:57 pmRNSTotal Voting Rights
23rd Jul 20207:00 amRNSChange of Adviser
23rd Jul 20207:00 amRNSFull Year Trading Update
2nd Jul 202010:11 amRNSTotal Voting Rights
16th Jun 202012:00 pmRNSDirectorate Change
1st Jun 20209:29 amRNSTotal Voting Rights
11th May 202011:00 amRNSStatement re Update on 2019 AGM Resolution Vote
1st May 202012:24 pmRNSTotal Voting Rights
22nd Apr 202010:11 amRNSHolding(s) in Company
21st Apr 20207:26 amRNSDirector/PDMR Shareholding
20th Apr 202010:19 amRNSHolding(s) in Company
20th Apr 20207:00 amRNSCOVID-19 Update
14th Apr 202010:07 amRNSHolding(s) in Company
9th Apr 20205:33 pmRNSIssue of Shares
2nd Apr 20209:50 amRNSTotal Voting Rights
27th Mar 20203:37 pmRNSHolding(s) in Company
9th Mar 20207:00 amRNSInterim results for 6 months ended 31 Dec 2019
4th Mar 20207:00 amRNSAcquisition of Marker Gene Technologies
2nd Mar 20203:43 pmRNSTotal Voting Rights
2nd Mar 20208:00 amRNSBlock listing Interim Review
4th Feb 202010:49 amRNSTotal Voting Rights
30th Jan 20207:00 amRNSAbcam expands cell engineering capabilities
28th Jan 20202:31 pmRNSHolding(s) in Company
28th Jan 20202:29 pmRNSDirector/PDMR Shareholding
14th Jan 20207:00 amRNSAppointment of Chief Financial Officer
10th Jan 20207:00 amRNSHalf Year Trading Update
2nd Jan 20209:45 amRNSTotal Voting Rights
2nd Jan 20207:00 amRNSTransaction complete between Abcam and Expedeon
19th Dec 201910:05 amRNSHolding(s) in Company
4th Dec 20193:37 pmRNSHolding(s) in Company
2nd Dec 20193:25 pmRNSDirector/PDMR Shareholding
2nd Dec 20199:30 amRNSTotal Voting Rights
21st Nov 201911:42 amRNSHolding(s) in Company
14th Nov 20197:00 amRNSAbcam Capital Markets Event
13th Nov 20194:45 pmRNSResult of AGM
11th Nov 20197:00 amRNSAbcam to acquire proteomics & immunology business
6th Nov 20199:06 amRNSDirector/PDMR Shareholding
1st Nov 201910:55 amRNSTotal Voting Rights
2nd Oct 20194:28 pmRNSHolding(s) in Company
2nd Oct 20191:49 pmRNSDirector/PDMR Shareholding
1st Oct 20192:22 pmRNSTotal Voting Rights
30th Sep 20191:35 pmRNSAnnual Financial Report
26th Sep 20192:30 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.